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Ovarian	cancer	has	several	unique	characteristics	among	
adult	solid	tumors:	the	highest	risk	of	thromboembolism	from	
the	disease	burden	itself	and	related	treatments,	survival	ben-
efit	of	extensive	cytoreductive	surgery	to	minimize	residual	
tumor	even	in	cases	of	peritoneal	seeding,	and	the	strongest	
hereditary	portion	in	adult	solid	tumors.
Risk	factors	for	venous	thromboembolic	disease	includes	
active	cancer,	advanced	stage,	cancer	type	such	as	gyneco-
logic	cancers,	regional	bulky	lymphadenopathy	with	extrinsic	
vascular	compression,	familial	and/or	acquired	hypercoagu-
lability,	medical	comorbidities,	poor	performance	status,	and	
old	age	[1].	Ovarian	cancer	is	the	one	of	the	bulky	malignant	
tumors	of	the	peritoneal	cavity,	and	therefore,	we	can	assume	
that	there	will	be	a	very	high	risk	of	thromboembolism	in	such	
patients.	The	risk	of	thromboembolism	is	related	to	secret-
ing	factors	from	the	tumor	such	as	tissue	factors,	reduced	
physical	activity,	and	chemotherapy.	Extensive	cytoreductive	
surgery	to	minimize	residual	tumor	is	essential	for	the	best	
treatment	outcomes	in	terms	of	disease	specific	survival	in	the	
management	of	ovarian	cancer.	Classically,	extensive	surgery	
and	pelvic	surgery	are	classified	as	one	of	the	risk	factors	for	
surgery-related	thromboembolism.	Contrary	to	common	be-
lief,	extensive	cytoreductive	surgery	is	not	related	to	the	risk	
of	postoperative	thromboembolism	in	patients	with	ovarian	
cancer	[2,3].	This	may	be	explained	by	the	fact	that	the	risk	of	
thromboembolism	is	related	closely	with	tumor	burden	rather	
than	the	surgical	procedure	itself	while	providing	dual	throm-
boprophylaxis	consisting	of	gradient	stockings	and	enoxa-
parin	administration.	The	risk	of	thromboembolism	should	
be	carefully	evaluated	whenever	there	is	suspicious	ovarian	
cancer,	and	clinical	suspicion	is	most	important.	Symptoms	of	
thromboembolism	such	as	dyspnea	and/or	leg	edema	can	be	
easily	ignored	because	ascites,	pleural	effusion,	or	lymphede-
ma	is	commonly	identified	in	ovarian	cancer	patients.	There-
fore,	careful	and	objective	evaluation	is	required	for	ovarian	
cancer	patients	with	such	symptoms.
In	this	issue,	Kawaguchi	et	al.	revealed	that	D-dimer	level	
of	<1.5	µg/mL	may	be	used	as	the	criteria	to	exclude	the	
possibility	of	venous	thromboembolism	in	a	single	center,	
retrospective	study	[4].	The	sensitivity,	specificity,	positive	
predictive	value,	and	negative	predictive	value	are	100%,	62%,	
33%,	100%	if	using	cut-off	value	of	D-dimer	level	>1.5	µg/mL.	
D-dimer	is	not	expensive	and	very	simple	to	evaluate.	Because	
thromboembolism	may	result	in	a	life-threatening	event,	early	
detection	of	thromboembolism	is	obviously	very	important.	
Prospective	studies	for	subclinical	detection	of	thrombo-
embolism	using	D-dimer	and/or	thromboembolism-related	
symptoms	are	required	to	confirm	the	cost-effectiveness	and/
or	survival	benefit.	New	recommendations	on	the	guidelines	
of	thromboembolism	is	required	based	on	current	evidence	
and	results	from	future	clinical	trials.
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